



GlycoMimetics, Inc.
Investor Relations Department
9708 Medical Center Drive
Rockville, MD 20860
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: GLYC

| | |
|---------------|--------------------------|
| Last Trade: | 13.00 |
| Trade Time: | 4:00 PM ET 05/26/2017 |
| Change: | -0.89 (6.407%) |
| Day Range | 12.31 - 13.67 |
| 52-Week Range | 3.82 - 16.94 |
| Volume | 3,760,905 |


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow's breakthrough treatments.

GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company's inception in 2003, we have developed a robust, diver... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 05/25/2017 [GlycoMimetics' GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia](#)
- 05/24/2017 [GlycoMimetics Announces Pricing of Public Offering of Common Stock](#)
- 05/22/2017 [GlycoMimetics Announces Proposed Public Offering of Common Stock](#)
- 05/18/2017 [GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, A Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML](#)
- 05/17/2017 [GlycoMimetics' GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia](#)

Upcoming Events [\[View all \]](#)

- 06/07/2017 2:00 PM ET [Jefferies 2017 Global Healthcare Conference](#)

Events [\[View all \]](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- 03/01/2017 [Annual Report \(10-K\)](#)
- 04/20/2017 [Proxy Statement \(DEF 14A\)](#)
- 05/08/2017 [Quarterly Report \(10-Q\)](#)
- 11/04/2016 [Quarterly Report \(10-Q\)](#)
- 08/04/2016 [Quarterly Report \(10-Q\)](#)